Tiago Fauth
Stock Analyst at Wells Fargo
(1.31)
# 3,414
Out of 4,761 analysts
134
Total ratings
33.65%
Success rate
-11.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $17 | $9.19 | +84.98% | 1 | Feb 20, 2025 | |
| INSM Insmed | Maintains: Overweight | $85 → $107 | $81.06 | +32.00% | 3 | Feb 19, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Equal-Weight | $41 → $4 | $3.08 | +29.87% | 1 | Feb 10, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $79 → $112 | $29.54 | +279.15% | 3 | Jan 31, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $14 → $11 | $1.25 | +780.00% | 2 | Jan 13, 2025 | |
| VRNA Verona Pharma | Maintains: Overweight | $64 → $74 | $67.96 | +8.89% | 3 | Jan 8, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $75 → $88 | $42.59 | +106.62% | 7 | Dec 20, 2024 | |
| SVRA Savara | Initiates: Overweight | $8 | $2.69 | +197.40% | 1 | Dec 20, 2024 | |
| MNKD MannKind | Initiates: Overweight | $9 | $5.76 | +56.25% | 1 | Dec 20, 2024 | |
| KROS Keros Therapeutics | Maintains: Overweight | $88 → $111 | $11.02 | +907.26% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $68 | $50.69 | +34.15% | 1 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $11.13 | +97.66% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $54.53 | +37.54% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $380 | $361.10 | +5.23% | 4 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $207 → $233 | $250.59 | -7.02% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $35 → $2 | $2.37 | -15.61% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $1.61 | +3,750.93% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $152.43 | -41.61% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $16.27 | +213.46% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $68.25 | +75.82% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $120 | $2.42 | +4,858.68% | 6 | May 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $21.27 | -81.19% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $4.96 | +182.26% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.42 | +852.38% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $8.25 | +215.15% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.03 | +824.09% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $27.52 | +194.33% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.41 | +1,860.30% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.28 | +993.75% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.12 | +2,935.71% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $4.51 | +3,225.94% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $36.85 | -21.30% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $3.65 | +256.16% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $1.92 | +577.08% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.83 | +9.29% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $644.48 | -47.24% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $303.01 | -14.52% | 1 | Apr 28, 2021 |
Amicus Therapeutics
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $9.19
Upside: +84.98%
Insmed
Feb 19, 2025
Maintains: Overweight
Price Target: $85 → $107
Current: $81.06
Upside: +32.00%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Equal-Weight
Price Target: $41 → $4
Current: $3.08
Upside: +29.87%
Tectonic Therapeutic
Jan 31, 2025
Maintains: Overweight
Price Target: $79 → $112
Current: $29.54
Upside: +279.15%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $14 → $11
Current: $1.25
Upside: +780.00%
Verona Pharma
Jan 8, 2025
Maintains: Overweight
Price Target: $64 → $74
Current: $67.96
Upside: +8.89%
Ultragenyx Pharmaceutical
Dec 20, 2024
Maintains: Overweight
Price Target: $75 → $88
Current: $42.59
Upside: +106.62%
Savara
Dec 20, 2024
Initiates: Overweight
Price Target: $8
Current: $2.69
Upside: +197.40%
MannKind
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $5.76
Upside: +56.25%
Keros Therapeutics
Dec 11, 2024
Maintains: Overweight
Price Target: $88 → $111
Current: $11.02
Upside: +907.26%
Nov 26, 2024
Maintains: Overweight
Price Target: $56 → $68
Current: $50.69
Upside: +34.15%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $11.13
Upside: +97.66%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $54.53
Upside: +37.54%
Aug 20, 2024
Maintains: Overweight
Price Target: $350 → $380
Current: $361.10
Upside: +5.23%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $207 → $233
Current: $250.59
Upside: -7.02%
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $2.37
Upside: -15.61%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $1.61
Upside: +3,750.93%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $152.43
Upside: -41.61%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $16.27
Upside: +213.46%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $68.25
Upside: +75.82%
May 26, 2023
Reiterates: Outperform
Price Target: $120
Current: $2.42
Upside: +4,858.68%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $21.27
Upside: -81.19%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.96
Upside: +182.26%
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.42
Upside: +852.38%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $8.25
Upside: +215.15%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.03
Upside: +824.09%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $27.52
Upside: +194.33%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.41
Upside: +1,860.30%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.28
Upside: +993.75%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.12
Upside: +2,935.71%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $4.51
Upside: +3,225.94%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $36.85
Upside: -21.30%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $3.65
Upside: +256.16%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $1.92
Upside: +577.08%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.83
Upside: +9.29%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $644.48
Upside: -47.24%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $303.01
Upside: -14.52%